Document:

Exhibit
10.1

TWENTY SECOND AMENDMENT TO

SECOND AMENDED AND RESTATED

LIMITED PARTNERSHIP AGREEMENT OF

CORPORATE
OFFICE PROPERTIES, L.P.

THIS TWENTY SECOND
AMENDMENT (the “Amendment”) to the Second Amended and Restated Limited
Partnership Agreement of Corporate Office Properties, L.P., a Delaware limited
partnership (the “Partnership”), is made and entered into as of January 9,
2007, by and among the undersigned parties.

Recitals

A.            The Partnership is a limited
partnership organized under the Delaware Revised Uniform Limited Partnership
Act (the “Act”) and governed by that certain Second Amended and Restated
Limited Partnership Agreement dated as of January, 1999, as amended by that
certain First Amendment to Second Amended and Restated Limited Partnership Agreement
dated as of  December 21, 1999, that
certain Second Amendment to Second Amended and Restated Limited Partnership
Agreement dated as of December 21, 1999, that certain Third Amendment to Second
Amended and Restated Limited Partnership Agreement dated as of  September 29, 2000, that certain Fourth
Amendment to Second Amended and Restated Limited Partnership Agreement dated as
of November 27, 2000, that certain Fifth Amendment to Second Amended and
Restated Limited Partnership Agreement dated as of January 25, 2001, that
certain Sixth Amendment to Second Amended and Restated Limited Partnership
Agreement dated as of April 6, 2001, that certain Seventh Amendment to the
Second Amended and Restated Partnership Agreement dated as of August 30, 2001,
that certain Eighth Amendment to the Second Amended and Restated Partnership
Agreement dated September 14, 2001, that certain Ninth Amendment to the Second
Amended and Restated Partnership Agreement dated October 16, 2001, that certain
Tenth Amendment to the Second Amended and Restated Partnership Agreement dated
December 29, 2001, that certain Eleventh Amendment to the Second Amended and
Restated Partnership Agreement dated December 15, 2002, that certain Twelfth
Amendment to the Second Amended and Restated Partnership Agreement dated June
2, 2003, that certain Thirteenth Amendment to the Second Amended and Restated
Partnership Agreement dated August 11, 2003, that certain Fourteenth Amendment
to the Second Amended and Restated Partnership Agreement dated December 18,
2003, that certain Fifteenth Amendment to the Second Amended and Restated
Partnership Agreement dated  January 31,
2004, that certain Sixteenth Amendment to the Second Amended and Restated
Partnership Agreement dated April 15, 2004, that certain Seventeenth Amendment
to the Second Amended and Restated Partnership Agreement dated September 23,
2004, that certain Eighteenth Amendment to the Second Amended and Restated
Partnership Agreement dated April 18, 2005, that certain Nineteenth Amendment
to the Second Amended and Restated Partnership Agreement dated July 8, 2005,
that certain Twentieth Amendment to the Second Amended and Restated Partnership
Agreement dated June 29, 2006 and that certain Twenty First Amendment to the
Second Amended and Restated Partnership Agreement dated July 20, 2006 (as
amended, the “Agreement”).

B.            The sole general partner of the
Partnership is Corporate Office Properties Trust, a real estate investment
trust formed under the laws of the State of Maryland (the “General Partner”).

C.            The General Partner is the owner of
1,000 shares of beneficial interest in W&M Business Trust, a Maryland
business trust (“W&M”), which represent one hundred percent (100%) of the
beneficial interests in W&M (the “W&M Beneficial Interests”).

D.            Pursuant to a Purchase Agreement and
Agreement and Plan of Merger, dated as of December 21, 2006 (the “Merger
Agreement”) by and among the General Partner, the Partnership, W&M and
Nottingham Village, Inc., a Maryland corporation (“NVI”), NVI is being merged
with and into W&M (the “Merger”).

E.             In connection with the Merger, the
General Partner is issuing to the shareholders of NVI, in a private offering,
531,667 of its 5.60 % Series K Cumulative Redeemable Convertible Preferred
Shares of beneficial interest (the “Series K Preferred REIT Shares”) and
3,161,000 of its Common Shares of beneficial interest (the “Common REIT Shares”
and, collectively with the Series K Preferred REIT Shares, the “REIT Shares”).

F.             As required under Sections 4.2(B)
and (C) of the Agreement, the General Partner intends to transfer (or cause to
be transferred) the property received in consideration for the REIT Shares,
which transfer shall be accomplished through the contribution to the
Partnership of all of the General Partner’s rights, title and interest in the
W&M Beneficial Interests following the merger of NVI with and into W&M,
to or for the benefit of the Partnership in exchange for 531,667 additional
Partnership Interests in the Partnership having designations, rights and preferences
substantially similar to the economic rights of the holders of the Series K
Preferred REIT Shares (the “Series K Preferred Units”) and 3,161,000 additional
common Partnership Interests in the Partnership (the “Common Units”).

G.            The General Partner desires to amend
the Agreement to acknowledge the contribution of the property received in
consideration for the REIT Shares by the General Partner to the Partnership in
exchange for such number of Series K Preferred Units and Common Units.  Unless otherwise defined herein, all
capitalized terms used in this Amendment shall have the same meanings as set
forth in the Agreement.

NOW THEREFORE, in
consideration of the foregoing and of the mutual premises set forth herein, the
General Partner, intending to be legally bound hereby, hereby amends the
Agreement as follows, effective as of the date set forth above.

1.             The foregoing recitals to this
Amendment are hereby incorporated in and made a part of this Amendment.

 2
 

(a)           Upon consummation of the Merger, the
General Partner shall contribute the property received in consideration for the
REIT Shares to the Partnership.

(b)           Upon the contribution of the property
received in consideration for the REIT Shares to the Partnership by the General
Partner, and in accordance with Section 4.2(B) of the Agreement, the
Partnership shall issue to the General Partner 531,667 Series K Preferred
Units, equal to the number of Series K Preferred REIT Shares issued by the
General Partner in connection with the Merger, and 3,161,000 Common Units,
equal to the number of Common REIT Shares issued by the General Partner in
connection with the Merger.

(c)            For purposes of the Agreement,
including the maintenance of Capital Accounts, the General Partner shall be
treated as making a Capital Contribution of $181,473,868.94, equal to the value
ascribed pursuant to the Merger Agreement to the Series K Preferred REIT Shares
and Common REIT Shares issued in the Merger.

(d)           The General Partner is hereby
amending Exhibit 1 to the Agreement by substituting for the existing
addendum to Exhibit 1 the Addendum to Exhibit 1 in the form
attached hereto to reflect the issuance of the Series K Preferred Units and
Common Units to the General Partner.

2.             Except as explicitly modified by
this Amendment, all of the provisions of the Agreement are hereby ratified and
confirmed, and shall remain in full force and effect.

3.             This Amendment shall take effect
upon the contribution of the property received in consideration for the REIT
Shares to the Partnership by the General Partner, and in the event such
contribution is not made, this Amendment shall be of no force or effect.

(SIGNATURE
PAGE FOLLOWS)

 3
 

In witness
whereof, the General Partner has executed this Amendment as of the day and year
first above written.

	
  

  	
  CORPORATE OFFICE PROPERTIES TRUST,

  
	
   

  	
  a Maryland Real Estate Investment Trust

  
	
   

  	
   

  
	
   

  	
  By:

  	
      /s/ Roger A. Waesche, Jr.

  
	
   

  	
  Name:

  	
  Roger A. Waesche, Jr.

  
	
   

  	
  Title:

  	
  Executive Vice President and Chief

  Operating Officer

  
				

 

 4

 

Exhibit 1 Addendum

 

Schedule
of Partners

 

	
  General Partner

  	
   

  	
  Common Units of Partnership Units

  	
   

  	
  Series G Preferred

  Units

  	
   

  	
  Series H

  Preferred

  Units

  	
   

  	
  Series I

  Preferred

  Units

  	
   

  	
  Series J

  Preferred

  Units

  	
   

  	
  Series K

  Preferred

  Units

  	
   

  
	
  Corporate Office Properties Trust

  	
   

  	
  43,987,789

  	
   

  	
  2,200,000

  	
   

  	
  2,000,000

  	
   

  	
   

  	
   

  	
  3,390,000

  	
   

  	
  531,667

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Limited Partners and Preferred
  Limited Partners

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Jay H. Shidler

  	
   

  	
  452,878

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Shidler Equities, L.P.

  	
   

  	
  2,995,439

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Clay W. Hamlin, III

  	
   

  	
  559,917

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  LBCW Limited Partnership

  	
   

  	
  2,831,107

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Robert L. Denton

  	
   

  	
  400,000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  James K. Davis

  	
   

  	
  51,589

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  John E. De B. Blockey, Trustee of the John
  E. de B. Blockey Living Trust dated 9/12/88

  	
   

  	
  300,625

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Frederick K. Ito Trust

  	
   

  	
  20,340

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  June Y. I. Ito Trust

  	
   

  	
  20,335

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  RP Investments, LLC

  	
   

  	
  100,000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Denise J. Liszewski

  	
   

  	
  23,333

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Samuel Tang

  	
   

  	
  4,389

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Lawrence J. Taff

  	
   

  	
  13,733

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Kimberly F. Aquino

  	
   

  	
  2,937

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  M.O.R. XXIX Associates Limited Partnership

  	
   

  	
  148,381

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  M.O.R. 44 Gateway Associates Limited
  Partnership

  	
   

  	
  1

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  John Parsinen

  	
   

  	
  49,434

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  M.O.R. Commons Limited Partnership

  	
   

  	
  7

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  John Edward De Burgh Blockey and Sanda
  Juanita Blockey

  	
   

  	
  10,476

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Lynn Hamlin

  	
   

  	
  51,411

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Housing Affiliates, Inc.

  	
   

  	
  4,402

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Reingle Corp.

  	
   

  	
  730

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Joseph Tawil

  	
   

  	
  2,160

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  The Lovejoy Trust

  	
   

  	
  59,528

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  The Century Trust

  	
   

  	
  59,528

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  A. Charles Wilson & Betty S. Wilson Trust

  	
   

  	
  5,908

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Harold & Renee Holland

  	
   

  	
  4,320

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Irwin Hoffman

  	
   

  	
  1,880

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Rouse 1988 Trust

  	
   

  	
  2,160

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CB Management, L.L.C.

  	
   

  	
  2,497

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Patriot Partner, L.L.C.

  	
   

  	
  25,000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  National Prostate Cancer Coalition

  	
   

  	
  400

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  John A. Luetkemeyer, Jr.

  	
   

  	
  38,954

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Eugene H. Schreiber and Richard E. Levine,
  Trustees U/A Sarah R. Schapiro dated 3/2/76 (Trust 113)

  	
   

  	
  38,954

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Eugene H. Schreiber and Richard E. Levine,
  Trustees U/A J. Mark Schapiro dated 3/27/02 f/b/o J.M. Schapiro (Trust 159)

  	
   

  	
  10,114

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Lawrence G. Rief

  	
   

  	
  2,526

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Thomas F. Mullan III

  	
   

  	
  58,857

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Erin L. Mullan

  	
   

  	
  9,055

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Norman W. Wilder

  	
   

  	
  22,637

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  The Nichols School

  	
   

  	
  300

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Johns Hopkins University

  	
   

  	
  200

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  University of Pennsylvania Friends of Penn
  Tennis

  	
   

  	
  70,500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Episcopal Academy

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Bryn Mawr Presbyterian Church

  	
   

  	
  150

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Arthur Ashe Youth Tennis & Education

  	
   

  	
  300

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Heritage Foundation

  	
   

  	
  200

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Volunteers in Medicine

  	
   

  	
  500

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  TRC Associates Limited Partnership

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  352,000

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  52,446,381

  	
   

  	
  2,200,000

  	
   

  	
  2,000,000

  	
   

  	
  352,000

  	
   

  	
  3,390,000

  	
   

  	
  531,667

  	
   

  

 

 

	
  Series

  Preferred

  Units

  	
   

  	
  Preferred Limited

  Partner

  	
   

  	
  No. of

  Preferred

  Units

  	
   

  	
  Liquidation

  Preference

  Per

  Preferred

  Unit

  	
   

  	
  Priority

  Percentage

  Return *

  	
   

  	
  Priority

  	
   

  	
  Conversion

  Factor

  	
   

  	
  Conversion

  Commencement

  Date

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  G

  	
   

  	
  General Partner

  	
   

  	
  2,200,000

  	
   

  	
  $

  	
  25

  	
   

  	
  8

  	
  %

  	
  Senior

  	
   

  	
  None

  	
   

  	
  N/A

  	
   

  
	
  H

  	
   

  	
  General Partner

  	
   

  	
  2,000,000

  	
   

  	
  $

  	
  25

  	
   

  	
  7.5

  	
  %

  	
  Senior

  	
   

  	
  None

  	
   

  	
  N/A

  	
   

  
	
  I

  	
   

  	
  TRC Associates

  Limited

  Partnership

  	
   

  	
  352,000

  	
   

  	
  **

  	
   

  	
  ***

  	
   

  	
  Senior

  	
   

  	
  .5/1

  	
   

  	
  September 23,

  2004

  	
   

  
	
  J

  	
   

  	
  General Partner

  	
   

  	
  3,390,000

  	
   

  	
  $

  	
  25

  	
   

  	
  7.625

  	
  %

  	
  Senior

  	
   

  	
  None

  	
   

  	
  N/A

  	
   

  
	
  K

  	
   

  	
  General
  Partner

  	
   

  	
  531,667

  	
   

  	
  $

  	
  50

  	
   

  	
  5.60

  	
  %

  	
  Senior

  	
   

  	
  ****

  	
   

  	
  January
  10,

  2007

  	
   

  

 

*           Priority Return Percentage is expressed as a percentage of
the Liquidation Preference per Distribution Period. See the Agreement for the
definitions of “Priority Return Percentage,” “Liquidation Preference” and
“Distribution Period.”

 

**        Liquidation Preference Per Series I
Preferred Unit shall equal $25.00 plus all accrued and unpaid distributions
thereon. In determining the Liquidation Preference, unpaid distributions shall
accrue and be compounded on a quarterly basis.

 

***      Priority Return Percentage for the Series
I Preferred Units shall be governed by Section 4 of the Seventeenth Amendment.
The Distribution Period for the Series I Preferred Units shall be each calendar
quarter ending on March 31, June 30, September 30 and December 31, of each
year.

 

****    The
Series K Preferred REIT Shares are convertible, at the option of the holder
thereof, at any time, in whole or in part, into the number of fully paid and
nonassessable shares of authorized but previously unissued Common Shares
obtained by dividing (1) an amount equal to the aggregate Liquidation
Preference (as defined in the Articles Supplementary designating such shares)
of the Series K Preferred REIT Shares to be converted by (2) an amount equal to
(A) the Calculation Price (as defined in the Merger Agreement) multiplied by
(B) 1.25. Upon such conversion of the Series K Preferred REIT Shares, the
Series K Preferred Units shall simultaneously be converted into a like number
of Common Units.LICENSE AGREEMENT

       LICENSE  AGREEMENT  ("the  Agreement"),  dated December ___, 2006, by and
among  Dr.  David P. Summers, an individual residing  at  3158  Canterbury  Ln.,
Montgomery, TX  77354  ("Summers"),  T.W.  Owen, an individual residing at 10635
Lessona  St.,  Las  Vegas,  NV 89141 ("Owen," and  together  with  Summers,  the
"Licensor"), and Datastand Technologies,  Inc., an Indiana corporation having an
office  at  8333  Weston  Road,  Suite 106, Woodbridge,  Ontario  L4L  8E2  (the
"Licensee").

                                   RECITALS:

       WHEREAS, Licensor is the inventor of certain technologies relating to the
use of fungi, plants, or animals for  the  production  of  anti-inflammatory and
analgesic  products  used to treat and cure inflammatory diseases,  and  is  the
owner of the entire right,  title  and  interest in and to certain Patent Rights
(defined below) relating to such technologies;

       WHEREAS,     Licensor desires to have  the  Patent  Rights  developed and
commercialized and is willing to grant a license thereunder; and

       WHEREAS,     Licensee desires to obtain a license under the Patent Rights
upon the terms and conditions hereinafter set forth.

       NOW  THEREFORE,  in  consideration of the mutual covenants and agreements
herein, and other good and valuable consideration, the adequacy, sufficiency and
receipt of which are hereby acknowledged, the parties hereto agree as follows:

                                   ARTICLE I
                                  Definitions

       1.1   Definitions.  As  used in this Agreement, the following terms shall
have the following meanings:

       (a)   "Improvement" means  any  improvement, addition, or modification of
an invention claimed in the Patent Rights and shall include, without limitation,
any patentable invention that is (i) not  included in the Patent Rights and (ii)
is dominated by one or more Valid Claims of the Patent Rights.

       (b)   "Licensed Product" means any product  or  part  thereof,  that: (i)
absent the license granted hereunder, would infringe one or more Valid Claims of
the Patent Rights; or (ii) is manufactured by using a Licensed Process or  that,
when used, practices a Licensed Process.

       (c)   "Licensed  Process"  means  any  process  that,  absent the license
granted hereunder, would infringe one or more Valid Claims of the  Patent Rights
or which uses a Licensed Product.

                                       1

<PAGE>
       (d)   "Patent Rights" means:

             (i)    the United States provisional patent applications  listed on
Exhibit A attached hereto;

             (ii)   any  patent  applications  resulting  from  the  provisional
applications   listed   on   Exhibit  A,  and  any  divisionals,  continuations,
continuation-in-part applications,  and  continued prosecution applications (and
their relevant international equivalents) of the provisional patent applications
listed  on  Exhibit  A  and of such patent applications  that  result  from  the
provisional applications listed on Exhibit A, and the resulting patents;

             (iii)  any patents  resulting  from  reissues,  re-examinations, or
extensions  (and  their  relevant  international  equivalents)  of  the  patents
described in clauses (i) and (ii) of this subsection 1.1(d); and

             (iv)   international  (non-United  States) patent applications  and
provisional  applications  filed  after  the  date  hereof   and   the  relevant
international  equivalents  to  divisionals, continuations, continuation-in-part
applications and continued prosecution  applications  of the patent applications
to the extent the claims are directed to subject matter  specifically  described
in the patents or patent applications referred to in clauses (i), (ii) and (iii)
of this subsection 1.1(d), and the resulting patents.

       (e)   "Term"  shall mean the term of this Agreement, which shall commence
on
the date hereof and shall  remain  in effect until the expiration or abandonment
of  the  last remaining Valid Claim of  any  issued  patents  and  filed  patent
applications  within  the Patent Rights, unless earlier terminated in accordance
with the provisions of  this  Agreement,  in which case the Term shall terminate
upon the effective date of such termination.

       (f)   "Territory" means the following:  North  America  to include Mexico
and Canada (the "Territory").

       (g)   "Valid Claim" means either (i) a claim of an issued  patent  within
the Patent Rights that has not been held invalid by an administrative agency  or
court  of  competent  jurisdiction in any unappealed or unappealable decision or
(ii) a claim of a pending  application  that  has  not been abandoned or finally
rejected without the possibility of appeal or refilling.  The  invalidity  of  a
particular claim in one or more countries shall not invalidate such claim in the
remaining countries of the Territory.

                                   ARTICLE II
                                 License Grant

       2.1   License  Grant.  Subject  to  the  terms  and  conditions  of  this
Agreement,  Licensor  hereby grants to Licensee, and Licensee hereby accepts, an
exclusive, irrevocable,  perpetual  license  ("License")  in  the  Territory  to
develop and have developed,

                                       2

<PAGE>
to make and have made, to use and have used, to sell and have sold, and to lease
and have leased Licensed Products and Licensed Processes.

       2.2   Exclusivity.   Licensor  agrees that it shall not retain any rights
to, and shall not directly or indirectly  grant  any other licenses to, develop,
make,  use, sell, and lease Licensed Products in the  Territory  or  to  perform
Licensed Processes in the Territory during the Term.

       2.3   Exclusive Option to Improvements.

             (a)    Licensor  hereby  grants  to Licensee an exclusive option to
add Improvements to the Patent Rights.  Licensee  may exercise its option to add
such  Improvement  to  the  Patent  Rights by providing  Licensor  with  written
notification of Licensee's desire to  so  add  the  Improvement  to  the  Patent
Rights.  Upon Licensee's exercise of such right, such Improvement shall be added
to  the  Patent Rights and Exhibit A hereto shall be deemed to have been amended
to add the  invention  disclosure (and any related patent applications) covering
such Improvement.  Licensor shall not offer a license to such Improvement to any
third party.

             (b)    At Licensee's  option,  Licensor  shall  assign to Licensee,
without further consideration, its entire right, title and interest  in  and  to
each and every such Improvement.

       2.4   Sublicenses.  Licensee shall have the right to grant sublicenses of
its rights under Section 2.1.

       2.5   Right  of  First  Refusal.   Licensee shall have the Right of First
Refusal  in  the  sale of any additional Territorial  Licenses  for  the  Patent
Rights, together with sixty (60) days to consummate such transaction.

                                  ARTICLE III
                                 CONSIDERATION

       3.1   Consideration.   In  consideration  of  the License, Licensee shall
issue to Licensor an aggregate of two million (2,000,000)  shares  of its common
stock (the "Consideration Shares") as follows:

Upon  execution of this Agreement, Licensee shall issue to Licensor two  million
(2,000,000) shares of the common stock of Licensee, which is hereby acknowledged
and agreed  to  constitute  consideration  for  the  grant of the License in the
Territory;

The Consideration Shares shall be allocated among each  Licensor  in  the manner
specified on Exhibit B attached hereto.

                                       3

<PAGE>
                                   ARTICLE IV
                         Representations and Warranties

       4.1   Licensor's Representations and Warranties.  Each Licensor,  jointly
and severally, hereby warrants and represents to Licensee that:

       (a)   Authority.  This Agreement constitutes the legal, valid and binding
obligation of each Licensor, enforceable against each of them in accordance with
its  terms.  Upon the execution and delivery by each Licensor of this Agreement,
this Agreement  will  constitute the legal, valid and binding obligation of each
Licensor, enforceable against  each  of  them in accordance with its terms. Each
Licensor has the absolute and unrestricted right, power and authority to execute
and deliver this Agreement and to perform  its obligations under this Agreement,
and  such  action  has been duly authorized by  all  necessary  action  of  each
Licensor.

       (b)   Infringement;   No   Conflict;  Litigation.   No  patent  or  other
intellectual  property  right of any  third  party  is  infringed  or  has  been
challenged or threatened  in  any  way  by the Patent Rights or the technologies
relating to the Patent Rights.  To Licensor's  knowledge,  there is no patent or
patent application of any third party that may potentially infringe or otherwise
interfere with the Patent Rights.  Neither the execution and  delivery  of  this
Agreement  nor  the  consummation  or  performance  of  any  of the transactions
contemplated hereunder will, directly or indirectly (with or without  notice  or
lapse  of  time),  breach or give any governmental authority or other person the
right to challenge this  Agreement  or  any  of  the  transactions  contemplated
hereunder.   Licensor  has  not granted any other licenses with respect  to  the
Patent Rights.  Licensor is not  aware  of any existing or threatened litigation
concerning the Patent Rights.

       (c)   No Consent Required.  Licensor  is  not required to give any notice
to or obtain any consent from any person in connection  with  the  execution and
delivery  of  this  Agreement or the consummation or performance of any  of  the
transactions contemplated hereunder.

       (d)   Inventors;  Ownership.   Licensor  is  the  sole  inventor  of  the
technologies  relating to the Patent Rights.  Licensor is the sole and exclusive
owner of the entire  right, title and interest in and to the Patent Rights, free
and clear of all liens  or  other  encumbrances.  Licensor has full legal right,
authority to grant the exclusive License to Licensee as set forth herein.

       (f)   Securities Matters.

             (i)    Licensor acknowledges its understanding that the issuance of
the Consideration Shares hereunder is  intended  to  be exempt from registration
under  the  Securities  Act  of  1933,  as amended (the "Securities  Act").   In
furtherance thereof, each of Licensor hereby  jointly  and  severally represents
and warrants to the Licensee that it is an "accredited investor" as that term is
defined  in Rule 501 of the General Rules and Regulations under  the  Securities
Act.  Licensor is acquiring the Consideration Shares for

                                       4

<PAGE>
its own account as principal, not as a nominee or agent, for investment purposes
only, and  not with a view to, or for, resale, distribution or fractionalization
thereof in whole  or  in  part  and  no  other  person  has a direct or indirect
beneficial interest in such shares or any portion thereof.   Each  Licensor  has
the  financial  ability  to  bear  the  economic  risk  of its investment.  Each
Licensor has such knowledge and experience in financial and  business matters as
to  be capable of evaluating the merits and risks of the prospective  investment
in the  shares being issued to it hereunder.  Each Licensor has been provided an
opportunity  for  a reasonable period of time prior to the date hereof to obtain
additional information  concerning the issuance of the shares, Licensee, and all
other information to the  extent  Licensee  possesses  such  information  or can
acquire it without unreasonable effort or expense.

             (ii)   Licensor understands that the Consideration Shares will  not
be  registered  under  the  Securities  Act  or the securities laws of any state
thereof, nor is such registration contemplated.  Licensor understands and agrees
further  that  such shares must be held and may not  be  transferred  until  and
unless the shares  are  registered  under  the Securities Act and the securities
laws  of  any other jurisdiction or an exemption  from  registration  under  the
Securities  Act  and any applicable laws is available. Licensor understands that
legends stating that  the  shares  have not been registered under the Securities
Act  and  the  securities laws of any other  jurisdiction  and  setting  out  or
referring to the  restrictions  on  the transferability and resale of the shares
will be placed on all documents evidencing the shares.

       (g)   Full Disclosure. No representation  or warranty of Licensor in this
Agreement  omits  to  state a material fact necessary  to  make  the  statements
herein, in light of the  circumstances  in which they were made, not misleading.
There is no fact known to Licensor that has  specific  application to the Patent
Rights and that materially adversely affects or, as far  as  can  be  reasonably
foreseen, materially threatens the Patent Rights that has not been set  forth in
this Agreement.

       4.2   Licensee's Representations and Warranties.

       (a)   Authority.  This Agreement constitutes the legal, valid and binding
obligation  of  Licensee,  enforceable  against  Licensee in accordance with its
terms.  Upon  the execution and delivery by Licensee  of  this  Agreement,  this
Agreement will  constitute  the legal, valid and binding obligation of Licensee,
enforceable against Licensee  in  accordance  with  its  terms. Licensee has the
absolute and unrestricted right, power and authority to execute and deliver this
Agreement and to perform its obligations under this Agreement,  and  such action
has been duly authorized by all necessary action of Licensee.

       (b)   Issuance  of Consideration Shares.  The Consideration Shares,  when
issued  in  accordance  with   the   terms  hereof  and  on  the  basis  of  the
representations and warranties of set  forth  herein  and  paid  for  as  herein
provided, shall be duly and validly issued, fully paid, and non-assessable.

                                       5

<PAGE>
                                   ARTICLE V
                               Patent Prosecution

       5.1   Responsibility  for  Patent  Rights.  Licensor shall prepare, file,
prosecute, and maintain all of the Patent Rights.   Licensor  and  its appointed
patent  attorneys  shall  use reasonable efforts to copy Licensee on all  patent
correspondence as follows:  (a)  documents received from any patent office shall
be provided to Licensee promptly after  receipt; (b) any document to be filed in
any patent office shall be provided in draft form to Licensee sufficiently prior
to such document's filing to allow for review  and  comment by Licensee; and (c)
documents filed with any patent office shall be provided  to  Licensee  promptly
after  filing.  Licensee  shall have reasonable opportunities to advise Licensor
and shall cooperate with Licensor in such filing, prosecution and maintenance.

       5.2   Payment of Expenses.  Licensee shall be responsible for the payment
of all reasonable and necessary fees  and costs, including reasonable attorney's
fees, relating to the filing, prosecution  and  maintenance of the Patent Rights
during the Term.

       5.3   Abandonment.  In the event that Licensor  desires  to  abandon  any
patent  or  patent  application within the Patent Rights, Licensor shall provide
Licensee with reasonable  prior  written  notice of such intended abandonment or
decline of responsibility, and Licensee shall have the right, at its expense, to
prepare, file, prosecute, and maintain the relevant Patent Rights.

                                   ARTICLE VI
                       Indemnity and Defense Obligations

       6.1   Indemnity  by  Licensor.   Each  of  Licensor  shall,  jointly  and
severally,  indemnify  and  hold  harmless Licensee,  and  its  representatives,
shareholders,  directors,  officers,   employees,   agents,   subsidiaries,  and
affiliates  (collectively,  the  "Licensee  Indemnified  Persons"),   and  shall
reimburse  the  Licensee  Indemnified  Persons  for  any loss, liability, claim,
damage,  expense (including costs of investigation and  defense  and  reasonable
attorneys' fees and expenses) or diminution of value, whether or not involving a
third party  claim (collectively, "Damages"), arising from or in connection with
the following: (a) any breach of any representation or warranty made by Licensor
in this Agreement  and  any  other  certificate, document, writing or instrument
delivered by Licensor pursuant to this  Agreement;  and  (b)  any  breach of any
covenant   or  obligation  of  Licensor  in  this  Agreement  or  in  any  other
certificate,  document,  writing or instrument delivered by Licensor pursuant to
this Agreement.

       6.2   Indemnity by  Licensee.  Licensee shall indemnify and hold harmless
Licensor, and its representatives, shareholders, directors, officers, employees,
agents, subsidiaries, and affiliates  (collectively,  the  "Licensor Indemnified
Persons"), and shall reimburse the Licensor Indemnified Persons  for  any  loss,
liability,  claim, damage, expense (including costs of investigation and defense
and reasonable  attorneys' fees and expenses) or diminution of value, whether or
not involving a third  party claim (collectively, "Damages"), arising from or in
connection with the following: (a) any

                                       6

<PAGE>
breach of any representation  or warranty made by Licensee in this Agreement and
any other certificate, document,  writing  or  instrument  delivered by Licensee
pursuant to this Agreement; and (b) any breach of any covenant  or obligation of
Licensee  in  this Agreement or in any other certificate, document,  writing  or
instrument delivered by Licensee pursuant to this Agreement.

       6.3   Third-Party Claims.

       (a)   "Third-Party  Claim" means any claim against any Indemnified Person
by a third party, whether or not involving a Proceeding.  Promptly after receipt
by a person entitled to indemnification  pursuant  to Sections 6.1 or 6.2 hereof
(an  "Indemnified Person") of notice of the assertion  of  a  Third-Party  Claim
against it, such Indemnified Person shall give notice to the person obligated to
indemnify  it  under such Section (an "Indemnifying Person") of the assertion of
such Third-Party  Claim,  provided  that  the failure to notify the Indemnifying
Person will not relieve the Indemnifying Person  of  any  liability  that it may
have  to  any  Indemnified  Person,  except  to the extent that the Indemnifying
Person demonstrates that the defense of such Third-Party  Claim is prejudiced by
the Indemnified Person's failure to give such notice.

       (b)   If an Indemnified Person gives notice to the Indemnifying Person of
the assertion of a Third-Party Claim, the Indemnifying Person  shall be entitled
to participate in the defense of such Third-Party Claim and, to  the extent that
it wishes (unless (i) the Indemnifying Person is also a Person against  whom the
Third-Party  Claim  is  made and the Indemnified Person determines in good faith
that joint representation would be inappropriate or (ii) the Indemnifying Person
fails to provide reasonable assurance to the Indemnified Person of its financial
capacity to defend such Third-Party  Claim  and  to provide indemnification with
respect to such Third-Party Claim), to assume the  defense  of  such Third-Party
Claim with counsel satisfactory to the Indemnified Person. After notice from the
Indemnifying  Person  to  the Indemnified Person of its election to  assume  the
defense of such Third-Party Claim, the Indemnifying Person shall not, so long as
it  diligently conducts such  defense,  be  liable  to  the  Indemnified  Person
hereunder  for  any  fees of other counsel or any other expenses with respect to
the defense of such Third-Party Claim, in each case subsequently incurred by the
Indemnified Person in  connection  with  the  defense of such Third-Party Claim,
other than reasonable costs of investigation. If the Indemnifying Person assumes
the  defense  of  a  Third-Party  Claim, (i) such assumption  will  conclusively
establish for purposes of this Agreement  that  the  claims  made in that Third-
Party Claim are within the scope of and subject to indemnification,  and (ii) no
compromise  or  settlement  of  such  Third-Party Claims may be effected by  the
Indemnifying Person without the Indemnified Person's Consent unless (A) there is
no finding or admission of any violation  of  Legal Requirement or any violation
of the rights of any person; (B) the sole relief  provided  is  monetary damages
that are paid in full by the Indemnifying Person; and (C) the Indemnified Person
shall  have  no liability with respect to any compromise or settlement  of  such
Third-Party Claims  effected  without  its  Consent.  If  notice  is given to an
Indemnifying   Person  of  the  assertion  of  any  Third-Party  Claim  and  the
Indemnifying Person  does  not,  within  ten  (10)  days  after  the Indemnified
Person's notice is given, give notice to the Indemnified Person of  its election
to assume

                                       7

<PAGE>
the defense of such Third-Party Claim, the Indemnifying Person will be  bound by
any determination made in such Third-Party Claim or any compromise or settlement
effected by the Indemnified Person.

       (c)   Notwithstanding  the foregoing, if an Indemnified Person determines
in good faith that there is a reasonable  probability  that  a Third-Party Claim
may adversely affect it other than as a result of monetary damages  for which it
would  be  entitled  to  indemnification  under  this Agreement, the Indemnified
Person may, by notice to the Indemnifying Person,  assume the exclusive right to
defend, compromise or settle such Third-Party Claim, but the Indemnifying Person
will not be bound by any determination of any Third-Party  Claim so defended for
the purposes of this Agreement or any compromise or settlement  effected without
its consent (which may not be unreasonably withheld or delayed).

       (d)   Notwithstanding any other provision of this Agreement, Licensor and
Licensee hereby consent to the nonexclusive jurisdiction of any court in which a
proceeding in respect of a Third-Party Claim is brought against any  Indemnified
Person for purposes of any claim that an Indemnified Person may have under  this
Agreement  with  respect  to  such Proceeding or the matters alleged therein and
agree that process may be served on Licensor and Licensee with respect to such a
claim anywhere in the world.

       (e)   With respect to any  Third-Party  Claim  subject to indemnification
hereunder: (i) both the Indemnified Person and the Indemnifying  Person,  as the
case  may  be,  shall keep the other person fully informed of the status of such
Third-Party Claim  and  any related proceedings at all stages thereof where such
person is not represented  by  its own counsel, and (ii) the parties agree (each
at  its  own expense) to render to  each  other  such  assistance  as  they  may
reasonably  require of each other and to cooperate in good faith with each other
in order to ensure the proper and adequate defense of any Third-Party Claim.

       6.4   Other  Claims.   A  claim  for  indemnification  for any matter not
involving a Third-Party Claim may be asserted by notice to the  party  from whom
indemnification is sought and shall be paid promptly after such notice.

                                  ARTICLE VII
                               Early Termination

       7.1   Voluntary Termination by Licensee. Licensee shall have the right to
terminate this Agreement, for any reason or no reason, upon at least ninety (90)
days  prior  written notice to Licensor, such notice to state the date at  least
ninety (90) days in the future upon which termination is to be effective.

       7.2   Termination  for  Default.   In  the  event  either party commits a
breach  of its obligations under this Agreement and fails to  cure  that  breach
within sixty  (60)  days after receiving written notice thereof, the other party
may terminate this Agreement immediately upon written notice to the other party.

                                       8

<PAGE>

                                  ARTICLE VIII
                            Confidential Information

       8.1   Information  Exchange.   During the Term, Licensee and Licensor are
likely  to  exchange  information  relating  to  the  Patent  Rights  and  their
commercial exploitation by Licensee.  The  following  provisions are intended to
protect the confidential or proprietary information of each party.

       (a)   Confidential Information. "Confidential Information" shall mean any
confidential or proprietary information furnished by one  party (the "Disclosing
Party")  to  the  other  party (the "Receiving Party") in connection  with  this
Agreement. Such Confidential  Information shall include, without limitation, any
information  relating  to  the Patent  Rights,  and  all  items,  materials  and
information which belong to  the Disclosing Party and are not generally known to
the public that has been or may hereafter be disclosed to Receiving Party by the
Disclosing Party or by the directors,  officers, employees, agents, consultants,
advisors  or other representatives, including  legal  counsel,  accountants  and
financial advisors  of  the  Disclosing  Party,  irrespective of the form of the
disclosure.  Confidential Information is intended  to be interpreted broadly and
includes  trade  secrets  and  other  proprietary  or  confidential  information
concerning   the   business  and  affairs  of  the  Disclosing  Party,   product
specifications, data,  know-how,  formulae,  compositions,  processes,  designs,
sketches,  photographs,  graphs,  drawings, samples, inventions and ideas, past,
current, and planned research and development, current and planned manufacturing
or distribution methods and processes,  customer  lists, current and anticipated
customer  requirements, price lists, supplier lists,  market  studies,  business
plans, computer  software  and programs (including object code and source code),
computer   software  and  database   technologies,   systems,   structures   and
architectures  (and  related  processes,  formulae,  composition,  improvements,
devices,  know-how,  inventions, discoveries, concepts, ideas, designs,  methods
and  information); financial  statements,  financial  projections  and  budgets,
historical  and  projected  sales, capital spending budgets and plans, the names
and  backgrounds  of  key  personnel,  and  personnel  training  techniques  and
materials.   Confidential  Information   also   includes  all  notes,  analyses,
compilations, studies, summaries and other material  prepared  by  the Receiving
Party  containing  or  based,  in  whole  or  in  part,  upon  any  Confidential
Information.

       (b)   Obligations.  During and after the Term, the Receiving Party  shall
(i)  maintain  Confidential  Information  of  the  Disclosing  Party  in  strict
confidence,  except  that  the  Receiving  Party  may  disclose  or  permit  the
disclosure  of  any  Confidential  Information   to   its  directors,  officers,
employees,  consultants,  and  advisors  who  are  obligated   to  maintain  the
confidential nature of such Confidential Information and who need  to  know such
Confidential  Information  for  the  purposes  of  this Agreement; (ii) use such
Confidential Information solely for the purposes of  this  Agreement;  and (iii)
allow  its trustees or directors, officers, employees, consultants, and advisors
to reproduce  the  Confidential Information only to the extent necessary for the
purposes  of  this Agreement,  with  all  such  reproductions  being  considered
Confidential Information.

                                       9

<PAGE>
       (c)   Exceptions.  The  obligations  of the Receiving Party under Section
8.1(b)  above  shall  not  apply  to the extent that  the  Receiving  Party  can
demonstrate that certain Confidential  Information  (i) was in the public domain
prior  to  the  time of its disclosure under this Agreement;  (ii)  entered  the
public domain after  the  time  of  its  disclosure under this Agreement through
means other than an unauthorized disclosure resulting from an act or omission by
the Receiving Party; (iii) was independently  developed  or  discovered  by  the
Receiving  Party  without  use  of  the Confidential Information; (iv) is or was
disclosed to the Receiving Party at any time, whether prior to or after the time
of its disclosure under this Agreement,  by  a  third  party having no fiduciary
relationship   with   the   Disclosing   Party  and  having  no  obligation   of
confidentiality  with  respect  to  such Confidential  Information;  or  (v)  is
required to be disclosed to comply with  applicable laws or regulations, or with
a court or administrative order, provided  that  the  Disclosing  Party receives
reasonable prior written notice of such disclosure and the Receiving Party takes
all reasonable actions to obtain confidential treatment of such information and,
if possible, to minimize the extent of such disclosure.

       (d)   Ownership  and  Return. The Receiving Party acknowledges  that  the
Disclosing Party (or any third  party  entrusting  its  own  information  to the
Disclosing  Party)  claims  ownership  of  its  Confidential  Information in the
possession  of the Receiving Party. Upon the expiration or termination  of  this
Agreement, and at the request of the Disclosing Party, the Receiving Party shall
return  to  the  Disclosing  Party  all  originals,  copies,  and  summaries  of
documents,  materials,   and   other  tangible  manifestations  of  Confidential
Information in the possession or control of the Receiving Party, except that the
Receiving Party may retain one copy  of  the Confidential Information solely for
the purpose of monitoring its obligations under this Agreement.

       (e)   Right to Injunctive Relief. The  Receiving  Party acknowledges that
disclosure or distribution of Confidential Information or  use  of  Confidential
Information  contrary to the terms of this Agreement may cause irreparable  harm
to the Disclosing Party, for which damages at law may not be an adequate remedy,
and agrees that  the  provisions  of  this  Agreement  prohibiting disclosure or
distribution of the Confidential Information or use contrary  to  the provisions
hereof  may  be  specifically enforced through injunctive relief by a  court  of
competent jurisdiction  in  addition  to any and all other remedies available at
law or in equity.

                                   ARTICLE IX
                               General Provisions

       9.1   Governing Law. This Agreement  and  all  disputes arising out of or
related  to  this  Agreement,  or  the  performance,  enforcement,   breach   or
termination  hereof,  and  any  remedies  relating  thereto, shall be construed,
governed, interpreted and applied in accordance with  the  laws  of the State of
Nevada,  U.S.A.,  without  regard  to  conflict of laws principles, except  that
questions  affecting  the  construction  and  effect  of  any  patent  shall  be
determined  by  the  law of the country in which  the  patent  shall  have  been
granted.

                                       10

<PAGE>
       9.2   Force  Majeure.  Neither  party  will  be  responsible  for  delays
resulting from causes  beyond  the  reasonable  control of such party, including
without limitation fire, explosion, flood, war, strike,  or  riot, provided that
the nonperforming party uses commercially reasonable efforts to  avoid or remove
such  causes  of  nonperformance and continues performance under this  Agreement
with reasonable dispatch whenever such causes are removed.

       9.3   Amendment  and Waiver. This Agreement may be amended, supplemented,
or otherwise modified only  by  means  of  a  written  instrument signed by both
parties.   Any  waiver of any rights or failure to act in  a  specific  instance
shall relate only to such instance and shall not be construed as an agreement to
waive any rights or fail to act in any other instance, whether or not similar.

       9.4   Severability.  In  the  event  that any provision of this Agreement
shall  be  held  invalid or unenforceable for any  reason,  such  invalidity  or
unenforceability shall  not  affect  any  other provision of this Agreement, and
such provision shall be modified to preserve  (to  the  extent  possible)  their
original intent.

       9.5   Binding  Effect. This Agreement shall be binding upon and inure  to
the  benefit  of the parties  and  their  respective  permitted  successors  and
assigns.

       9.6   Headings.  All  headings  are  for  convenience  only and shall not
affect the meaning of any provision of this Agreement.

       9.7   Entire  Agreement. This Agreement constitutes the entire  agreement
between the parties with  respect to its subject matter and supersedes all prior
agreements or understandings between the parties relating to its subject matter.

       9.8   Further Assurances.   From  time  to  time,  each  party shall make
reasonable commercial efforts to take, or cause to be taken, all actions, and to
do, or cause to be done, all things reasonably necessary, proper  or  advisable,
including  as  required by applicable laws, to consummate and make effective  as
promptly as practicable the transactions contemplated by this Agreement.

       9.9   Notices.  All notices or other communications required or permitted
hereunder shall  be  in  writing  shall  be deemed duly given (a) if by personal
delivery, when so delivered, (b) if transmitted  by  facsimile,  (c)  if mailed,
three (3) business days after having been sent by registered or certified  mail,
return  receipt  requested,  postage  prepaid  and  addressed  to  the  intended
recipient  as  set  forth  below,  or  (d) if sent through an overnight delivery
service in circumstances to which such service guarantees next day delivery, the
day following being so sent:

             (1)    If to Licensors:
                           Dr. David P. Summers
                           3158 Canterbury Ln.
                           Montgomery, TX 77354

                                       11

<PAGE>
                           and
                           T.W. Owen
                           10635 Lessona St.
                           Las Vegas, NV 89141

             (2)    If to Licensee:

                           Datastand Technologies, Inc.
                           8333 Weston Road, Suite 106
                           Woodbridge, Ontario L4L 8E2
                           Attn: Nick Montesano, Chief Executive Officer
                           Facsimile: (416)-463-6940

Any  party  may change the address to which  notices  and  other  communications
hereunder are  to  be delivered by giving the other parties notice in the manner
herein set forth.

       9.10  Legal Representation  of  the  Parties. The parties agree that each
party was either represented by its own separate  and independent counsel or had
an  opportunity  to be so represented in connection with  this  Agreement.  This
Agreement  was  negotiated   by   the   parties   with   the  benefit  of  legal
representation,  and  any  rule  of  construction  or  interpretation  otherwise
requiring this Agreement to be construed or interpreted  against any party shall
not apply to any construction or interpretation hereof.

     [remainder of page intentionally left blank; signature page to follow]

                                       12

<PAGE>
       IN WITNESS WHEREOF, the parties have executed this  License  Agreement as
of the date first written above.

<TABLE>
<CAPTION>
LICENSOR:                                                          LICENSEE:
<S>                                 <C>                            <C>

______________________________                                     DATASTAND TECHNOLOGIES, INC.
DR. DAVID P. SUMMERS
                                                                   By:    ____________________
                                                                   Name:  Nick Montesano
________________________________                                   Title: Chief Executive Officer,
T. W. OWEN                                                         Chief Financials Officer, and Director

</TABLE>

                                       13

<PAGE>
                                   EXHIBIT A

                    List of Provisional Patent Applications

1.     "Composition   and  Method  of  Producing  Endogenous  Therapeutic  Anti-
Inflammatory Eiconasids  and  their  Metabolites by Exogenous or Oral Means," by
David P. Summers and T.W. Owen, (USPTO Serial Number 60/570,649).

2.     "Method and Process for Producing Anti-inflammatory Products from Fungi,"
by David P. Summers and T.W. Owen, (USPTO  Serial  Number  to  be  supplied upon
receipt).

                                       14

<PAGE>
                                   EXHIBIT B

                       ALLOCATION OF CONSIDERATION SHARES

The Consideration Shares shall be allocated among each Licensor as follows:

<TABLE>
<CAPTION>
Name of Licensor                                                 Percentage of Consideration Shares to be
                                                                 Allocated to Such Licensor
<S>                                                              <C>

David P. Summers                                                 50%

T.W. Owen                                                        50%

                                                           Total 100%

</TABLE>

                                       15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]